课题基金 / 基金详情

Developing a stable cell line expressing recombinant sclerostin

Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
批准号:
10385037
负责人:
Mo Chen
金额:
$29.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-20 至 2024-09-16

项目摘要

项目成果

Mo Chen的其他基金

相似基金

相关文献

中文摘要
翻译
1)抽象
英文摘要
1 Abstract 2 The temporomandibular joint (TMJ) is a complex joint system critical for dental occlusion, 3 mastication, respiration and speech. The TMJ is comprised of a network of muscles, 4 ligaments, and a fibrocartilaginous disc and condyle. Temporomandibular disorders (TMDs) 5 are a complex, heterogeneous group of pathologies involving the TMJ and associated 6 musculature. Degenerative types of TMDs, including TMJ osteoarthritis (OA), are debilitating, 7 compromise the quality of life. TMDs afflict over 10 million Americans at an annual cost of 8 ~$4 billion, per the NIDCR. Current TMJ OA treatments are typically two-fold, involving either 9 pain management or invasive surgeries, such as total joint replacements with high failure rates. 10 Regenerative medicine promises the recreation functional tissue that is lost from diseases. 11 Thus exploiting the regenerative capabilities of resident stem cells to repair TMJ may 12 represent a minimally invasive stem cell based treatment for TMJ OA. Sponsored by NIH 13 small business grant, we further developed StemGel®, a sustained-release formulation by 14 encapsulating sclerostin in hyaluronic acid (HA). Monthly injection of StemGel® efficiently 15 inhibits TMJ OA progression and regenerates cartilage in both rabbit and minipig TMJ OA 16 models. 17 The active ingredient of StemGel®, sclerostin is a glycosylated protein with 213 amino acids. 18 A mammalian expressing system is required to faithfully produce the post-translational 19 modification. Cell line development is a critical inflection point for therapeutic protein 20 manufacturing. The properties of the cell substrate and the events linked to cell substrate 21 can affect protein quality and safety, and further, the effective quality control on all aspects of 22 handling the cell substrate. The goal of this proposal is to develop Master Cell Bank 23 (MCB)/stable cell line expressing sclerostin to be readily transferred to the Contract 24 Development and Manufacturing Organization (CDMO) for massive production of the GMP 25 grade protein for pharmacokinetics and safety tests.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Innovative medical device to treat nonunion fracture for older adults
  • 批准号:
    10766444
  • 项目类别:
  • 资助金额:
    $29.94万
  • 财政年份:
    2023
  • 负责人:
    Mo Chen
  • 依托单位:
Small Molecules Promote Tendon Regeneration by Targeting Endogenous Stem Cells
  • 批准号:
    10258102
  • 项目类别:
  • 资助金额:
    $25.21万
  • 财政年份:
    2021
  • 负责人:
    Mo Chen
  • 依托单位:
Development of Drug Delivery Technology for Stem Cell Based TMJ Regeneration
  • 批准号:
    10010173
  • 项目类别:
  • 资助金额:
    $75.2万
  • 财政年份:
    2018
  • 负责人:
    Mo Chen
  • 依托单位:
Development of Drug Delivery Technology for Stem Cell Based TMJ Regeneration
  • 批准号:
    10225329
  • 项目类别:
  • 资助金额:
    $74.28万
  • 财政年份:
    2018
  • 负责人:
    Mo Chen
  • 依托单位:
海外基金